Patients with rare bone cancer still have low survival rates
the ONA take:
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.
A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).
Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.
Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.
Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- The Integration of Cannabis in Oncologic Care
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|